EUCTR2016-000678-40-CZ进行中（未招募）1 期
Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn’s Disease
Takeda Development Centre Europe Limited0 个研究点目标入组 385 人开始时间: 2016年5月18日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 385
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Any subject who meets the inclusion criteria for the qualifying vedolizumab clinical studies and meets any of the following criteria will qualify for entry into the study:
- •1. Received vedolizumab (excluding comparator or placebo subjects) during participation in a qualifying vedolizumab study.
- •2. In the opinion of the investigator, the subject is continuing to derive benefit from vedolizumab and continued treatment with vedolizumab is desired because there is no other comparable product available or the subject may be expected to develop worsening of disease if they were to modify treatment.
- •3. A male subject who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 18 weeks after last dose.
- •4. A female subject of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 18 weeks after last dose.
- •PK Substudy:
- •5. Received vedolizumab during participation in the C13008 protocol.
- •6. The subject will start the main XAP study on Q8W dosing.
- •7. The subject or, when applicable, the subject's legally acceptable
- •representative, has signed and dated a written ICF for the procedures
- •related to the XAP-PK substudy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 380
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •Any subject who meets any of the exclusion following criteria will not qualify for entry into the study:
- •1. For the subject’s particular clinical scenario, vedolizumab is currently available to the subject through commercial channels, including reimbursement.
- •2. Subject has any clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements or poses a risk to the subject being in the study.
- •3. If female, the subject is pregnant or lactating or intending to become pregnant before, during, or within 18 weeks after participating in this study; or intending to donate ova during such time period.
- •4. If male, the subject intends to donate sperm during the course of this study or for 18 weeks thereafter.
- •5. Subject has received a live vaccine in the last 18 weeks or is in need of a live vaccine during the study or up to 18 weeks after the last study dose.
研究者
相似试验
进行中（未招募）
1 期
Program to allow continuation of treatment with Entyvio (Vedolizumab IV) for patients with ulcerative colitis and Chron´s disease who previously participated in a clinical trial with this same treatmentlcerative Colitis and Crohn’s DiseaseMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.0Level: LLTClassification code 10013099Term: Disease CrohnsSystem Organ Class: 100000004856EUCTR2016-000678-40-HUTakeda Development Centre Europe Limited385
进行中（未招募）
1 期
Program to allow continuation of treatment with Entyvio (Vedolizumab IV) for patients with ulcerative colitis and Chron´s disease who previously participated in a clinical trial with this same treatmentEUCTR2016-000678-40-LVTakeda Development Centre Europe Limited385
进行中（未招募）
1 期
Program to allow continuation of treatment with Entyvio (Vedolizumab IV) for patients with ulcerative colitis and Chron¿s disease who previously participated in a clinical trial with this same treatmentEUCTR2016-000678-40-ITTAKEDA DEVELOPMENT CENTRE EUROPE LTD331
进行中（未招募）
1 期
Program to allow continuation of treatment with Entyvio (Vedolizumab IV) for patients with ulcerative colitis and Chron´s disease who previously participated in a clinical trial with this same treatmentlcerative Colitis and Crohn’s DiseaseMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.0Level: LLTClassification code 10013099Term: Disease CrohnsSystem Organ Class: 100000004856EUCTR2016-000678-40-BGTakeda Development Centre Europe Limited385
进行中（未招募）
3 期
A study to provide extended access to Vedolizumab IV for Patients with Ulcerative Colitis and Crohnâ??s Disease.CTRI/2017/01/007722Takeda Development Centre Asia Pvt Limited TDC Asia